Foundation Medicine
Point32Health Expands Coverage of Foundation Medicine CDx Tests for Patients With Advanced Cancer
FoundationOne CDx and FoundationOne Liquid CDx comprehensive genomic profiling tests will be available to Point32Health patients with advanced solid tumors.
UnitedHealthcare Issues New Policy Expanding Coverage of Precision Oncology Diagnostics
The private payor added new coverage criteria for sequencing tests in approved companion diagnostic indications, as well as prostate cancer risk assays.
Foundation Medicine, Boehringer Ingelheim Collaborate on CDx for Biliary Tract Cancer Drug
The companies will develop the FoundationOne CDx test as a companion diagnostic for Boehringer Ingelheim's BI 907828 in the US, Japan, and EU.
Foundation Medicine, Karyopharm Therapeutics Partnering on Endometrial Cancer CDx
The test would help identify patients who have advanced or recurrent TP53 wild-type endometrial cancer and could benefit from the experimental drug Xpovio.
FDA Approves Foundation Medicine Blood Test as CDx for Rozlytrek
FoundationOne Liquid CDx, a liquid biopsy test, is the only blood-based CDx approved for the targeted cancer therapy.
Nov 22, 2022